NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRYNGOLZA (olezarsen sodium) is a subcutaneous antisense oligonucleotide developed by Ionis Pharmaceuticals, approved December 19, 2024. The specific indication and mechanism of action are not yet disclosed in public labeling but align with Ionis' RNA-targeting platform. This represents a novel modality entry into a specialized therapeutic area.
Growth7.7 years to LOE
Early-stage growth phase with minimal current data; brand team is likely in build-out and launch execution mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Ionis Pharmaceuticals is hiring 1 role related to this product
Worked on TRYNGOLZA (AUTOINJECTOR) at Ionis Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.